{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:56:03Z","timestamp":1791406563105,"version":"4.3.3"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0385"],"award-info":[{"award-number":["W81XWH-16-1-0385"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.celrep.2026.117050","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:03:35Z","timestamp":1772643815000},"page":"117050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier"],"prefix":"10.1016","volume":"45","author":[{"given":"Saurabh K.","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesan","family":"Ramamoorthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika N.","family":"Kodumudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth E.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holm","family":"Bussler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan V.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiqiang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio A.","family":"Vazquez Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darwin C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Wiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo C.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Zauderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K.","family":"Koski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Czerniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2026.117050_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1172\/JCI6909","article-title":"Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells","volume":"104","author":"Dhodapkar","year":"1999","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.celrep.2026.117050_bib2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/fon.12.125","article-title":"Dendritic cell-based vaccines: barriers and opportunities","volume":"8","author":"Cintolo","year":"2012","journal-title":"Future Oncol."},{"key":"10.1016\/j.celrep.2026.117050_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/PPO.0000000000000607","article-title":"Current State of Cell Therapies for Breast Cancer","volume":"28","author":"Gautam","year":"2022","journal-title":"Cancer J."},{"key":"10.1016\/j.celrep.2026.117050_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101239","article-title":"Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development","volume":"95","author":"Gautam","year":"2024","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.celrep.2026.117050_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.celrep.2026.117050_bib6","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1158\/0008-5472.CAN-07-0878","article-title":"Development of vaccines for high-risk ductal carcinoma in situ of the breast","volume":"67","author":"Czerniecki","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117050_bib7","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1158\/1078-0432.CCR-16-1924","article-title":"Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2(pos) DCIS Independent of Route: Results of Randomized Selection Design Trial","volume":"23","author":"Lowenfeld","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117050_bib8","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1002\/cncr.26734","article-title":"HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ","volume":"118","author":"Sharma","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.celrep.2026.117050_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2326-6066.CIR-21-0454","article-title":"Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4(+) Th1 Responses and Potential Use as a Cancer Vaccine","volume":"10","author":"Basu","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.celrep.2026.117050_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004841","article-title":"Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma","volume":"10","author":"Ramamoorthi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.celrep.2026.117050_bib11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1158\/2326-6066.CIR-24-0630","article-title":"Antitumor CD4+ T helper 1 cells target and control the outgrowth of disseminated cancer cells","volume":"13","author":"Ramamoorthi","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.celrep.2026.117050_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/jamaoncol.2024.5371","article-title":"Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical Trial","volume":"11","author":"Han","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.celrep.2026.117050_bib13","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/1078-0432.CCR-07-4636","article-title":"Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"14","author":"Portera","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117050_bib14","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.celrep.2026.117050_bib15","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.3390\/jcm11092363","article-title":"Chemotherapy-Related Cognitive Impairment in Patients with Breast Cancer Based on Functional Assessment and NIRS Analysis","volume":"11","author":"Dur\u00e1n-G\u00f3mez","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.celrep.2026.117050_bib16","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1002\/cam4.4202","article-title":"Prevalence and predictors of peripheral neuropathy after breast cancer treatment","volume":"10","author":"Kamgar","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.celrep.2026.117050_bib17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1634\/theoncologist.2018-0184","article-title":"Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study","volume":"24","author":"Kang","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.celrep.2026.117050_bib18","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.celrep.2026.117050_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1261820","article-title":"Editorial: Cancer cell-intrinsic and -extrinsic factors affecting tumor immune evasion","volume":"14","author":"Sun","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2026.117050_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/19336918.2016.1197479","article-title":"Transmembrane semaphorins: Multimodal signaling cues in development and cancer","volume":"10","author":"Gurrapu","year":"2016","journal-title":"Cell Adh. Migr."},{"key":"10.1016\/j.celrep.2026.117050_bib21","doi-asserted-by":"crossref","first-page":"11780","DOI":"10.1073\/pnas.93.21.11780","article-title":"Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation","volume":"93","author":"Hall","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117050_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/1476-4598-9-251","article-title":"Roles of Sema4D and Plexin-B1 in tumor progression","volume":"9","author":"Ch'ng","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.celrep.2026.117050_bib23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2326-6066.CIR-18-0156","article-title":"Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function","volume":"7","author":"Clavijo","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.celrep.2026.117050_bib24","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1084\/jem.20072602","article-title":"Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages","volume":"205","author":"Sierra","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.celrep.2026.117050_bib25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/2326-6066.CIR-14-0171","article-title":"Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies","volume":"3","author":"Evans","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.celrep.2026.117050_bib26","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1158\/1078-0432.CCR-20-4792","article-title":"A Phase Ib\/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer","volume":"27","author":"Shafique","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117050_bib27","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1073\/pnas.0508825103","article-title":"Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis","volume":"103","author":"Basile","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117050_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13058-017-0864-z","article-title":"Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes","volume":"19","author":"Prabhakaran","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.celrep.2026.117050_bib29","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.188.9.1651","article-title":"Interferon gamma derived from CD4(+) T cells is sufficient to mediate T helper cell type 1 development","volume":"188","author":"Wakil","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.celrep.2026.117050_bib56","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.ymthe.2020.12.037","article-title":"Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway","volume":"29","author":"Jia","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.celrep.2026.117050_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.celrep.2026.117050_bib31","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood.2021014495","article-title":"Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2026.117050_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41416-020-01123-w","article-title":"Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer","volume":"124","author":"Zhang","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.celrep.2026.117050_bib33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.celrep.2026.117050_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170762","article-title":"Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target","volume":"133","author":"Ozbay Kurt","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.celrep.2026.117050_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","article-title":"Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion","volume":"13","author":"Lu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.celrep.2026.117050_bib36","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.celrep.2026.117050_bib37","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.2147\/OTT.S114708","article-title":"The role of semaphorin 4D in tumor development and angiogenesis in human breast cancer","volume":"9","author":"Jiang","year":"2016","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.celrep.2026.117050_bib38","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.4049\/jimmunol.1501293","article-title":"Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells","volume":"196","author":"Younis","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2026.117050_bib39","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3389\/fimmu.2020.01680","article-title":"The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion","volume":"11","author":"De Cicco","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2026.117050_bib40","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1002\/jcp.26896","article-title":"Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer","volume":"234","author":"Safarzadeh","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.celrep.2026.117050_bib41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-017-4594-9","article-title":"CD14+ HLA-DR-\/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation","volume":"168","author":"Speigl","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.celrep.2026.117050_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1074-7613(03)00175-4","article-title":"Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity","volume":"19","author":"Itano","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.117050_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.677036","article-title":"How Does B Cell Antigen Presentation Affect Memory CD4 T Cell Differentiation and Longevity?","volume":"12","author":"Welsh","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2026.117050_bib44","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/30996","article-title":"Help for cytotoxic-T-cell responses is mediated by CD40 signalling","volume":"393","author":"Bennett","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117050_bib45","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/30989","article-title":"A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell","volume":"393","author":"Ridge","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117050_bib46","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/31002","article-title":"T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117050_bib47","first-page":"2254","article-title":"[Involvement of immune semaphorins in the immune system]","volume":"47","author":"Kumanogoh","year":"2002","journal-title":"Tanpakushitsu Kakusan Koso"},{"key":"10.1016\/j.celrep.2026.117050_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ni1553","article-title":"Semaphorins and their receptors in immune cell interactions","volume":"9","author":"Suzuki","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.celrep.2026.117050_bib49","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","article-title":"Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells","volume":"74","author":"Goc","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117050_bib50","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1900635","article-title":"Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer","volume":"10","author":"J Gunderson","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.celrep.2026.117050_bib51","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117050_bib52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41379-018-0113-8","article-title":"Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis","volume":"32","author":"Lee","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.celrep.2026.117050_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.117050_bib54","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1158\/0008-5472.CAN-23-3325","article-title":"Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy","volume":"84","author":"Petroni","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117050_bib55","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2026.117050_bib57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2015.07.001","article-title":"Interferon-lambda: Immune Functions at Barrier Surfaces and Beyond","volume":"43","author":"Lazear","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.117050_bib58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2026.117050_bib59","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.celrep.2026.117050_bib60","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.4049\/jimmunol.166.4.2276","article-title":"IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma","volume":"166","author":"Beatty","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2026.117050_bib61","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s43018-023-00570-7","article-title":"Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-gamma is a major determinant of CD4(+) CAR T-cell antitumor activity","volume":"4","author":"Boulch","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.celrep.2026.117050_bib62","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/ni.2038","article-title":"Origins of CD4(+) effector and central memory T cells","volume":"12","author":"Pepper","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.celrep.2026.117050_bib63","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.4049\/jimmunol.2100852","article-title":"Tissue-Resident Memory CD4(+) T Cells Play a Dominant Role in the Initiation of Antitumor Immunity","volume":"208","author":"Zhang","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2026.117050_bib64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri1309","article-title":"NKT cells: what's in a name?","volume":"4","author":"Godfrey","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.celrep.2026.117050_bib65","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1038\/s41388-021-01880-9","article-title":"NK and NKT cells have distinct properties and functions in cancer","volume":"40","author":"Liu","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2026.117050_bib66","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1038\/cti.2016.14","article-title":"Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents","volume":"5","author":"Carreno","year":"2016","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.celrep.2026.117050_bib67","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fimmu.2018.01519","article-title":"CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: alpha-Galactosylceramide and Beyond","volume":"9","author":"King","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2026.117050_bib68","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ijc.20998","article-title":"Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load","volume":"116","author":"Molling","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.celrep.2026.117050_bib69","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.leukres.2004.06.005","article-title":"The peripheral blood Valpha24+ NKT cell numbers decrease in patients with haematopoietic malignancy","volume":"29","author":"Yoneda","year":"2005","journal-title":"Leuk. Res."},{"key":"10.1016\/j.celrep.2026.117050_bib70","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3892\/ol.2013.1226","article-title":"Ki-67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively","volume":"5","author":"Campos","year":"2013","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.celrep.2026.117050_bib71","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/j.1349-7006.2011.02053.x","article-title":"Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer","volume":"102","author":"Kato","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.celrep.2026.117050_bib72","first-page":"423","article-title":"Co-expression of plexin-B1 and Met in human breast and ovary tumours enhances the risk of progression","volume":"31","author":"Valente","year":"2009","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.celrep.2026.117050_bib73","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1172\/JCI60568","article-title":"ErbB-2 signals through Plexin-B1 to promote breast cancer metastasis","volume":"122","author":"Worzfeld","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.celrep.2026.117050_bib74","doi-asserted-by":"crossref","first-page":"32066","DOI":"10.1074\/jbc.M109.057166","article-title":"Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity","volume":"284","author":"Sun","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.celrep.2026.117050_bib75","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1182\/blood-2004-07-2885","article-title":"Sema4D induces angiogenesis through Met recruitment by Plexin B1","volume":"105","author":"Conrotto","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2026.117050_bib76","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0092-8674(00)80063-X","article-title":"Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates","volume":"99","author":"Tamagnone","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117050_bib77","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/ncb843","article-title":"The semaphorin 4D receptor controls invasive growth by coupling with Met","volume":"4","author":"Giordano","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.celrep.2026.117050_bib78","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-022-01919-8","article-title":"Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial","volume":"28","author":"Feigin","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2026.117050_bib79","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.4049\/jimmunol.1300692","article-title":"Differences in mouse and human nonmemory B cell pools","volume":"192","author":"Benitez","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2026.117050_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2023.07.004","article-title":"Human and mouse early B cell development: So similar but so different","volume":"261","author":"Korzhenevich","year":"2023","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.celrep.2026.117050_bib81","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","article-title":"Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species","volume":"50","author":"Zilionis","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.117050_bib82","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726001282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726001282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:40:49Z","timestamp":1791405649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124726001282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2211124726001282"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117050","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117050"}}